Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most investors see this drug as a failure, which explains the low valuation and general lack of interest.
So what inspires you to keep coming back here instead of moving on to more superior companies that will offer you greater returns?
The bullish minority is here because they think they know something that most of the world doesn't. If they're right, there's a lot of money to be made, and if they're wrong, they'll lose the same amount of money as the investors in other failed AD ventures.
Maybe the risk/reward is what makes this one so special, even if it ends up not working out in the end. There's a lot of money to be made if you can figure things out before everyone else does.
Or maybe some people just like gambling on nanocap biotech companies instead of going to a casino.
Of course, but it takes a few weeks to receive and process the data so the PR will probably have to wait until early December.
Probably just one of many things that get thrown out of balance in AD brains, but still interesting to see yet another research group showcase the potential of PKC activators.
Not sure if this has been mentioned already, but I noticed they filed a patent for treating ALS:
https://patents.justia.com/patent/20220184028
Looks like the options granted to directors a few months ago have been voided according to latest filings.
Agreed. Every day that passes without them diluting their stock at these prices is a good day.
Only 4 months left until last dose.
There is nothing to communicate here. If they attend a new conference, launch a new trial, or post new results, we'll know about it.
Crack open a cold one and enjoy the summer sun.
It was more than 4 patients that showed improvement if you include later trials, but clearly that hasn't convinced the market yet.
There are certainly some positive signals here but I'm still convinced the stock price isn't going anywhere until they post good results in a few months, and there's no guarantee they will.
Yes, that doesn't change what I wrote about the chart though.
The current trial is testing longer term efficacy of the drug, which is what really matters. Plenty of things can cause short-term cognitive improvements, but Alzheimer’s is a long-term disease that needs a long-term solution.
Even the Namenda trial showed improvement in the short-term iirc.
Whoever posted that picture failed to understand that the horizontal axis represents weeks, not hours.
This is also a bad example in general since the dosage wasn't optimal and the dosing interval was irregular. This was done before they had figured out how to properly administer the drug in humans, and before they figured out that weekly doses caused reduced efficacy over time due to PKC downregulation.
About $40-100 million.
Hopefully they wait until topline data is out before raising more cash. If all goes well that could be the last one.
You can find the latest warrant info in the ibox. Just subtract the ones that expired in April.
They'll probably just throw out a PR like for the previous trials. They announced a conference call before releasing "positive" results in 2017 and announced the results straight away in the PR for negative results in 2019.
Topline data should show patient scores after receiving the last dose and full data should show their scores after not receiving the drug for several months to see if any improvements linger.
If they can show improvement in the topline data that would be good news on its own, but if the full data maintains those improved scores that would be a sign that the drug not only benefits patients but that the benefits are also long-lasting.
As for shots on goal, I'd say it depends on how the topline data looks. The drug has never been tested in a longer trial like this so nobody knows what scores could look like after the first dosing cycle.
It tends to follow the NBI which was up today too, maybe not in exact percentages but at least the color.
Topline data is this year but full data won't be out until next year.
They have enough cash to survive until 2024 but that doesn't include additional trials, which they need for approval.
The cash they have needs to be spent on getting a drug approved so they can start earning revenues and stop diluting their stock.
Won't be a problem if management does the next cash raise after the trial rather than before.
They only have enough cash to finish the current trial. Spending that money on buybacks would be financially irresponsible.
The price makes more sense once you look at the market as a whole. Rate hikes and inflation are making everything more expensive and people are pulling their money out of the stock market as a result.
As long as there's no demand here it will keep dropping with the market.
Yeah, this stock is just following the index. Hard to find anything green in a market like this.
Potential and promise doesn't mean much when you're getting dragged down by a bear market.
It's going to get uglier and I'm sure we may even hit $4 soon enough. Won't be a real problem though unless management raises cash at those levels. Company has enough cash to ride this storm out so I hope they're smart enough to do just that.
It does offer some symptomatic relief iirc. Won't cure the disease or anything, but it does have a calming effect on otherwise agitated and confused patients in addition to pain relief.
Wouldn't surprise me if they did. I have no confidence whatsoever in the chairman of the board and hopefully stockholders will vote to replace him as soon as possible.
I bet he's the one responsible for handing out warrants like candy to his hedge fund buddies.
Downside risk is still a 100% loss. This is still a company with no revenues that will go bankrupt if it fails to find investors to keep it afloat.
Cash value doesn't mean much since the cash will have been completely spent by 2024.
Why anyone would take that quack seriously is a mystery to me.
SA is not a reliable source of information.
When they publish good results. There's no reason for the stock to rise before then, and it will probably even drop further if they decide to raise cash before then.
Probably won't include data from the 10 month checkup then. Final dose should be around October so maybe that's what they're publishing.
"Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial"
https://www.prnewswire.com/news-releases/synaptogenix-completes-patient-enrollment-in-nih-sponsored-phase-2b-alzheimers-disease-trial-301528016.html
Probably just the oral version that was tested in mice long ago.
Question is, are they planning to use this shelf before trial results or after?
I'm pretty sure it's just their annual option grant to directors, and these options don't vest until next year.
Trading volume and institutional ownership is too low for that to be true. What's more likely is that markets simply don't care about the company.
Yes, they have a poison pill that dilutes anyone acquiring more than 15% of the company without the board's consent.
Just look for "Shareholder rights plan" in their filings.
The science looks solid and Dr. Perry's approval certainly means a lot, but I feel this company still hasn't managed to convince the world about what it could do.
Maybe new trial results will change that.
To be fair, he's the chairman of the scientific advisory board and may be biased because of that.
Would be better to hear that from someone that has nothing to do with the company.
I think you misunderstood my example. Here's the formula for cashless exercise:
[(A-B) (X)] by (A) = S
A is market price
B is exercise price
X is the amount of exercised warrants
S is the amount of shares you receive
In this example that's (($24 - $12) x 200 warrants) / 24 = 100 shares
Cashless exercise of 100 warrants would give you 50 shares.
To get 100 shares you would have to either exercise 200 warrants cashless or 100 warrants plus $12 in cash for each warrant.
Either way, this only applies to prefunded warrants now according to the warrant terms. The other ones have to be paid with cash since they've been registered.
I took another look at the warrant terms and apparently the cashless exercise option only applies to the pre-funded warrants now. My bad.
It's an exercise, not sale. You have to exercise one warrant for one share no matter what, but then you also have the option to trade in additional warrants instead of cash depending on how big the difference is between market price and warrant exercise price.
"c) Cashless Exercise. This Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered to the Company within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;
(B) = the Exercise Price, as adjusted hereunder; and
(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise."
Also worth noting is that all the warrants allow for a cashless exercise, which lets investors pay with their warrants instead of cash.
So if the market price is $24 and the exercise price is $12, they can pay for 100 shares with either a) 100 $12 warrants and $1200 in cash or b) 200 $12 warrants.
The pre-funded warrants were sold for the same price as regular shares. The only difference is that instead of receiving shares the investors got warrants that cost almost nothing to exercise. The $0.04 warrants are old $0.01 ones that were adjusted because of the 1-for-4 reverse split.
"The purpose of using pre-funded warrants is to provide investors that have restrictions on their ability to own a company’s securities above a designated ownership threshold (typically, 9.99% or 19.99%) with the opportunity to invest additional capital without violating the investor’s ownership restrictions."
https://www.jdsupra.com/legalnews/practice-pointers-on-pre-funded-warrants-65100/